These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 10666513

  • 1. LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine.
    Schreiber R, Lowe D, Voerste A, De Vry J.
    Eur J Pharmacol; 2000 Jan 28; 388(2):R3-4. PubMed ID: 10666513
    [Abstract] [Full Text] [Related]

  • 2. Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition.
    Schlumberger C, Schäfer D, Barberi C, Morè L, Nagel J, Pietraszek M, Schmidt WJ, Danysz W.
    Behav Pharmacol; 2009 Feb 28; 20(1):56-66. PubMed ID: 19179851
    [Abstract] [Full Text] [Related]

  • 3. The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam.
    Tizzano JP, Griffey KI, Schoepp DD.
    Pharmacol Biochem Behav; 2002 Sep 28; 73(2):367-74. PubMed ID: 12117591
    [Abstract] [Full Text] [Related]

  • 4. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats.
    Cartmell J, Monn JA, Schoepp DD.
    J Pharmacol Exp Ther; 1999 Oct 28; 291(1):161-70. PubMed ID: 10490900
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity.
    Schlumberger C, Pietraszek M, Gravius A, Klein KU, Greco S, Morè L, Danysz W.
    Eur J Pharmacol; 2009 Nov 25; 623(1-3):73-83. PubMed ID: 19765575
    [Abstract] [Full Text] [Related]

  • 6. In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268).
    Fell MJ, Perry KW, Falcone JF, Johnson BG, Barth VN, Rash KS, Lucaites VL, Threlkeld PG, Monn JA, McKinzie DL, Marek GJ, Svensson KA, Nelson DL.
    J Pharmacol Exp Ther; 2009 Dec 25; 331(3):1126-36. PubMed ID: 19755662
    [Abstract] [Full Text] [Related]

  • 7. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344.
    Rorick-Kehn LM, Perkins EJ, Knitowski KM, Hart JC, Johnson BG, Schoepp DD, McKinzie DL.
    J Pharmacol Exp Ther; 2006 Feb 25; 316(2):905-13. PubMed ID: 16223873
    [Abstract] [Full Text] [Related]

  • 8. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
    Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ, Nisenbaum ES, Catlow JT, Kingston AE, Giera DD, Herin MF, Monn JA, McKinzie DL, Schoepp DD.
    J Pharmacol Exp Ther; 2007 Apr 25; 321(1):308-17. PubMed ID: 17204749
    [Abstract] [Full Text] [Related]

  • 9. Group II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and D-amphetamine models of schizophrenia.
    Profaci CP, Krolikowski KA, Olszewski RT, Neale JH.
    Psychopharmacology (Berl); 2011 Jul 25; 216(2):235-43. PubMed ID: 21327758
    [Abstract] [Full Text] [Related]

  • 10. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.
    Marek GJ, Wright RA, Schoepp DD, Monn JA, Aghajanian GK.
    J Pharmacol Exp Ther; 2000 Jan 25; 292(1):76-87. PubMed ID: 10604933
    [Abstract] [Full Text] [Related]

  • 11. The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity.
    Henry SA, Lehmann-Masten V, Gasparini F, Geyer MA, Markou A.
    Neuropharmacology; 2002 Dec 25; 43(8):1199-209. PubMed ID: 12527469
    [Abstract] [Full Text] [Related]

  • 12. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity.
    Galici R, Echemendia NG, Rodriguez AL, Conn PJ.
    J Pharmacol Exp Ther; 2005 Dec 25; 315(3):1181-7. PubMed ID: 16123306
    [Abstract] [Full Text] [Related]

  • 13. Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists.
    Nakazato A, Kumagai T, Sakagami K, Yoshikawa R, Suzuki Y, Chaki S, Ito H, Taguchi T, Nakanishi S, Okuyama S.
    J Med Chem; 2000 Dec 14; 43(25):4893-909. PubMed ID: 11123999
    [Abstract] [Full Text] [Related]

  • 14. Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.
    Linden AM, Shannon H, Baez M, Yu JL, Koester A, Schoepp DD.
    Psychopharmacology (Berl); 2005 Apr 14; 179(1):284-91. PubMed ID: 15619115
    [Abstract] [Full Text] [Related]

  • 15. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.
    Monn JA, Valli MJ, Massey SM, Hansen MM, Kress TJ, Wepsiec JP, Harkness AR, Grutsch JL, Wright RA, Johnson BG, Andis SL, Kingston A, Tomlinson R, Lewis R, Griffey KR, Tizzano JP, Schoepp DD.
    J Med Chem; 1999 Mar 25; 42(6):1027-40. PubMed ID: 10090786
    [Abstract] [Full Text] [Related]

  • 16. Effects of the group II metabotropic glutamate receptor agonist, LY354740 on schedule-controlled behaviour in rats.
    Moore NA, Rees G, Monn JA.
    Behav Pharmacol; 1999 May 25; 10(3):319-25. PubMed ID: 10780246
    [Abstract] [Full Text] [Related]

  • 17. Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice.
    Spooren WP, Gasparini F, van der Putten H, Koller M, Nakanishi S, Kuhn R.
    Eur J Pharmacol; 2000 May 26; 397(1):R1-2. PubMed ID: 10844118
    [Abstract] [Full Text] [Related]

  • 18. Neuroprotective and behavioral effects of the selective metabotropic glutamate mGlu(1) receptor antagonist BAY 36-7620.
    De Vry J, Horváth E, Schreiber R.
    Eur J Pharmacol; 2001 Oct 05; 428(2):203-14. PubMed ID: 11675037
    [Abstract] [Full Text] [Related]

  • 19. Transepithelial transport of the group II metabotropic glutamate 2/3 receptor agonist (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) and its prodrug (1S,2S,5R,6S)-2-[(2'S)-(2'-amino)propionyl]aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY544344).
    Varma MV, Eriksson AH, Sawada G, Pak YA, Perkins EJ, Zimmerman CL.
    Drug Metab Dispos; 2009 Jan 05; 37(1):211-20. PubMed ID: 18838508
    [Abstract] [Full Text] [Related]

  • 20. Potent, stereoselective, and brain region selective modulation of second messengers in the rat brain by (+)LY354740, a novel group II metabotropic glutamate receptor agonist.
    Schoepp DD, Johnson BG, Wright RA, Salhoff CR, Monn JA.
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Aug 05; 358(2):175-80. PubMed ID: 9750002
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.